Ideal for: VEGF inhibition studies, bone metastasis development, hypoxia and tumor progression

786-O is a hypertriploid renal cell carcinoma (RCC) cell line that was one of the first and most commonly used RCC cell lines established. 786-O cells have mutant Hippel-Lindau (VHL), which is the most common tumor suppressor mutation in clear cell RCC (ccRCC). 786-O cells also have altered hypoxia-induced factor (HIF) and vascular endothelia growth factor (VEGF) pathways. 786-O cells were used to demonstrate that VHL mutations are not sufficient to induce a hypoxic phenotype in RCC cells. The VHL gene was also found to play a distinct role in the HIF and VEGF signaling pathways in 786-O cells1.

786-O cells were isolated from a primary tumor sample, but they form tibial bone metastases in nude mice when injected directly into the tibia or into circulation via the cardiac ventricle. Additionally, 786-O cells express elevated levels of mesenchymal genes (eg vimentin), suggesting that xenografts of 786-O cells in the OncoRat could be used to study RCC metastasis in vivo.

768-O cells have homozygous p53, PTEN, and p16 (CDKN2A) mutations. Additionally, it expresses parathyroid hormone (PTH) like peptide. 786-O has proven useful in cancer stem cell studies and bone metastasis.

Request A Proposal
Download Publications

Enabling Case Study: 786-O Tumor Kinetics in OncoRat

The OncoRat demonstrated a 100% engraftment rate for the 786-O xenograft model, providing an ideal host for 786-O tumor biology.

786-O products & services

  • Xenograft efficacy studies, including collection of blood, tissues and tumor for ADME, PK/PD and analysis.
  • Weekly or bi-weekly tumor sampling via fine need aspiration (FNA). For longitudinal evaluation of drug exposure, histology and gene expression.
  • OncoRats off-the-shelf for engraftment at the customers facility.
  1. Brodaczewska KK, Szczylik C, Fiedorowicz M, Porta C, Czarnecka AM. Choosing the right cell line for renal cell cancer research. Molecular cancer. 2016;15(1):83-83.